Outcomes in COVID-19 BMS mAbs studies

0 0.5 1 1.5+ All studies -36% 1 210 Improvement, Studies, Patients Relative Risk Hospitalization -36% 1 210 Viral clearance 4% 1 210 RCTs -36% 1 210 Early -36% 1 210 BMS mAbs for COVID-19 c19early.org November 2025 FavorsBMS mAbs Favorscontrol
0 0.25 0.5 0.75 1 1.25 1.5 1.75 2+ Corada (DB RCT) -36% 1.36 [0.31-5.92] hosp. 4/104 3/106 Improvement, RR [CI] Treatment Control Tau​2 = 0.00, I​2 = 0.0%, p = 0.7 Early treatment -36% 1.36 [0.31-5.92] 4/104 3/106 36% higher risk All studies -36% 1.36 [0.31-5.92] 4/104 3/106 36% higher risk 1 BMS mAbs COVID-19 study c19early.org November 2025 Tau​2 = 0.00, I​2 = 0.0%, p = 0.7 Effect extraction pre-specified(most serious outcome) Favors BMS mAbs Favors control 0 0.25 0.5 0.75 1 1.25 1.5 1.75 2+ Corada (DB RCT) -36% 1.36 [0.31-5.92] hosp. 4/104 3/106 Improvement, RR [CI] Treatment Control Tau​2 = 0.00, I​2 = 0.0%, p = 0.7 Early treatment -36% 1.36 [0.31-5.92] 4/104 3/106 36% higher risk All studies -36% 1.36 [0.31-5.92] 4/104 3/106 36% higher risk 1 BMS mAbs COVID-19 hospitalization result c19early.org November 2025 Tau​2 = 0.00, I​2 = 0.0%, p = 0.7 Favors BMS mAbs Favors control 0 0.25 0.5 0.75 1 1.25 1.5 1.75 2+ Corada (DB RCT) -36% 1.36 [0.31-5.92] hosp. 4/104 3/106 Improvement, RR [CI] Treatment Control Tau​2 = 0.00, I​2 = 0.0%, p = 0.7 Early treatment -36% 1.36 [0.31-5.92] 4/104 3/106 36% higher risk All studies -36% 1.36 [0.31-5.92] 4/104 3/106 36% higher risk 1 BMS mAbs COVID-19 serious outcome c19early.org November 2025 Tau​2 = 0.00, I​2 = 0.0%, p = 0.7 Effect extraction pre-specified(most serious outcome) Favors BMS mAbs Favors control 0 0.25 0.5 0.75 1 1.25 1.5 1.75 2+ Corada (DB RCT) 20% 0.80 [0.57-1.12] recov. time 105 (n) 106 (n) Improvement, RR [CI] Treatment Control Tau​2 = 0.00, I​2 = 0.0%, p = 0.19 Early treatment 20% 0.80 [0.57-1.12] 105 (n) 106 (n) 20% lower risk All studies 20% 0.80 [0.57-1.12] 105 (n) 106 (n) 20% lower risk 1 BMS mAbs COVID-19 recovery result c19early.org November 2025 Tau​2 = 0.00, I​2 = 0.0%, p = 0.19 Favors BMS mAbs Favors control 0 0.25 0.5 0.75 1 1.25 1.5 1.75 2+ Corada (DB RCT) 4% 0.96 [0.87-1.06] viral+ 104 (n) 106 (n) Improvement, RR [CI] Treatment Control Tau​2 = 0.00, I​2 = 0.0%, p = 0.45 Early treatment 4% 0.96 [0.87-1.06] 104 (n) 106 (n) 4% lower risk All studies 4% 0.96 [0.87-1.06] 104 (n) 106 (n) 4% lower risk 1 BMS mAbs COVID-19 viral clearance result c19early.org November 2025 Tau​2 = 0.00, I​2 = 0.0%, p = 0.45 Favors BMS mAbs Favors control 0 0.25 0.5 0.75 1 1.25 1.5 1.75 2+ Corada (DB RCT) -36% 1.36 [0.31-5.92] hosp. 4/104 3/106 Improvement, RR [CI] Treatment Control Tau​2 = 0.00, I​2 = 0.0%, p = 0.7 Early treatment -36% 1.36 [0.31-5.92] 4/104 3/106 36% higher risk All studies -36% 1.36 [0.31-5.92] 4/104 3/106 36% higher risk 1 BMS mAbs COVID-19 Randomized Controlled Trial c19early.org November 2025 Tau​2 = 0.00, I​2 = 0.0%, p = 0.7 Effect extraction pre-specified(most serious outcome) Favors BMS mAbs Favors control 0 0.25 0.5 0.75 1 1.25 1.5 1.75 2+ Corada (DB RCT) -36% 1.36 [0.31-5.92] hosp. 4/104 3/106 Improvement, RR [CI] Treatment Control Tau​2 = 0.00, I​2 = 0.0%, p = 0.7 Early treatment -36% 1.36 [0.31-5.92] 4/104 3/106 36% higher risk All studies -36% 1.36 [0.31-5.92] 4/104 3/106 36% higher risk 1 BMS mAbs COVID-19 peer reviewed studies c19early.org November 2025 Tau​2 = 0.00, I​2 = 0.0%, p = 0.7 Effect extraction pre-specified(most serious outcome) Favors BMS mAbs Favors control 0 0.25 0.5 0.75 1 1.25 1.5 1.75 2+ Corada (DB RCT) -36% 1.36 [0.31-5.92] hosp. 4/104 3/106 Improvement, RR [CI] Treatment Control Corada (DB RCT) 17% 0.83 [0.70-0.98] progression 104 (n) 106 (n) Corada (DB RCT) 20% 0.80 [0.57-1.12] recov. time 105 (n) 106 (n) Corada (DB RCT) 4% 0.96 [0.87-1.06] viral+ 104 (n) 106 (n) Corada (DB RCT) 0% 1.00 [0.89-1.11] viral+ 104 (n) 106 (n) Corada (DB RCT) 3% 0.97 [0.76-1.25] viral+ 104 (n) 106 (n) BMS mAbs COVID-19 outcomes c19early.org November 2025 Favors BMS mAbs Favors control